Precision combination therapy after car-t for b-cell lymphoma
Part of Cancer clinical trials.
This study tests a new combination of medicines, chosen based on your tumor's specific features, for people whose lymphoma did not respond to CD19 CAR-T therapy. The goal is to find a more effective treatment option for this difficult situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a type of large B-cell lymphoma (a blood cancer), such as diffuse large B-cell lymphoma or high-grade B-cell lymphoma
- You have already received CD19 CAR-T cell therapy, and your lymphoma did not shrink or it came back after that treatment
- You can provide a tumor tissue sample (new or old) that tests positive for a protein called CD20
- You are generally able to care for yourself (ECOG score 0, 1, or 2) and have adequate organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
This study tests a new combination of drugs for people with large b-cell lymphoma that has come back or not responded to the first treatment. It aims to see if this combination can help control the cancer and prepare for a type of cell therapy called liso-cel.
This study tests a new CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded after at least two prior treatments, including an FDA-approved CAR T-cell therapy. The goal is to see if this new therapy can help when previous CAR T treatment has not worked.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
This trial tests a new type of CAR-T cell therapy that may be better at remembering and attacking lymphoma cells. It is for people with large B-cell lymphoma that has not responded to standard treatments or has come back.
Hear when a new Large B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.